--- canonical_name: Vitamin K1 alternate_names: Phylloquinone, Phytonadione, Phytomenadione canonical_topic: Vitamin K1 for Health & Longevity short_topic_lc: vitamin_k1 creation_date: 2026-0705-0052 creator_ai_fullname: Opus 4.8 --- # Vitamin K1 for Health & Longevity

Evidence Review created on 07/05/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Phylloquinone, Phytonadione, Phytomenadione ## Motivation Vitamin K1 (phylloquinone) is the plant form of vitamin K, the nutrient found mainly in green leafy vegetables such as spinach, kale, and broccoli. Its most familiar job is helping blood clot normally, which is why it is given to newborns and used in hospitals to reverse certain blood thinners. Without enough of it, the body cannot switch on a small family of proteins that manage where calcium goes. Beyond clotting, researchers noticed decades ago that some of these same vitamin K–activated proteins live in bone and in the walls of arteries, where they seem to help keep calcium in the skeleton and out of blood vessels. That observation, together with population studies linking higher vitamin K1 intake to fewer fractures, less artery hardening, and even a lower chance of dying during follow-up, has moved this everyday nutrient into longevity conversations. This review examines what is actually known about vitamin K1 for long-term health: how it works, the strength of the evidence behind each proposed benefit, its risks and interactions, and how the plant form compares with the animal and fermented forms. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews from trusted experts and publications that discuss vitamin K1 and how it differs from the other forms of vitamin K. * [Differences between vitamin K1 and K2](https://www.foundmyfitness.com/episodes/differences-between-vitamin-k1-k2) - Rhonda Patrick A short, accessible clip in which the plant form (K1) and the animal/fermented form (K2) are contrasted, including why K1 goes mostly to the liver for clotting while circulating vitamin K supports arteries and bone. A good plain-language orientation to why the "form" of vitamin K matters. * [Vitamin K2: The Missing Nutrient](https://chriskresser.com/vitamin-k2-the-missing-nutrient/) - Chris Kresser A widely read overview that explains the practical differences between K1 and K2, dietary sources, and why the author argues K1 alone may not cover every vitamin K–dependent function. Useful for understanding the K1-versus-K2 debate from a functional-medicine viewpoint. * [The Surprising Longevity Benefits of Vitamin K](https://www.lifeextension.com/magazine/2014/9/the-surprising-longevity-benefits-of-vitamin-k) - Judy Ramirez A magazine feature summarizing the observational links between vitamin K intake and lower risks of artery calcification, cardiovascular disease, and death from any cause. It frames the nutrient explicitly through a longevity lens for a health-oriented readership. * [Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease](https://pubmed.ncbi.nlm.nih.gov/30791399/) - Halder et al., 2019 A narrative review that goes beyond clotting to compare how K1 and K2 behave in bone, vascular, and metabolic tissue. It is a strong single source for the biology underlying the extra-hepatic (outside-the-liver) claims made for vitamin K. * [Vitamin K – sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity](https://pubmed.ncbi.nlm.nih.gov/34472618/) - Mladěnka et al., 2022 A comprehensive narrative review covering dietary sources, absorption and turnover, deficiency, laboratory detection, therapeutic uses, and the unusually low toxicity of vitamin K. It is the most complete single reference for readers who want depth on phylloquinone specifically. ## Grokipedia * [Vitamin K](https://grokipedia.com/page/Vitamin_K) Grokipedia does not host a page dedicated solely to Vitamin K1; the phylloquinone form is described within its broader "Vitamin K" article, which covers the K1 and K2 forms, their functions in clotting and calcium handling, and dietary sources. ## Examine * [Vitamin K](https://examine.com/supplements/vitamin-k/) Examine's vitamin K page summarizes the human evidence for both forms, including the K1 (phylloquinone) doses studied for bone markers (roughly 0.1–5 mg/day), safety, and the well-established interaction with warfarin. It is an evidence-graded reference that distinguishes what is proven from what is only suggested. ## ConsumerLab * [Vitamin K Supplements Review](https://www.consumerlab.com/reviews/vitamin-k-supplements-review/vitamin-k/) ConsumerLab independently tests vitamin K products (including K1 supplements) for label accuracy and contamination, and it has reported products containing less vitamin K than labeled. This is the most relevant source for judging the real-world quality of specific brands. ## Systematic Reviews This section summarizes the highest-level pooled evidence — systematic reviews and meta-analyses — most relevant to vitamin K1 and long-term health. * [Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts](https://pubmed.ncbi.nlm.nih.gov/32359159/) - Shea et al., 2020 Pooling individual data from three large US cohorts, this analysis found that people with the lowest circulating phylloquinone had a meaningfully higher risk of death from any cause, though not a clearly higher risk of cardiovascular disease specifically. It is the single most cited source behind the "vitamin K1 and longevity" association. * [Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/16801507/) - Cockayne et al., 2006 This meta-analysis of randomized controlled trials (RCTs — studies that randomly assign participants to treatment or placebo) reported reduced fractures with vitamin K supplementation, but the effect was driven largely by high-dose K2 trials in Japan, limiting what can be concluded about K1. A foundational, if now dated, reference on vitamin K and bone. * [Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31119401/) - Chen et al., 2019 This review synthesized observational studies linking vitamin K status and intake to cardiovascular events and mortality, generally finding inverse associations of modest size. It is useful for gauging how consistent — and how uncertain — the population-level signal is. * [Vitamin K intake and the risk of fractures: A meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28445289/) - Hao et al., 2017 Focusing on dietary vitamin K intake rather than supplements, this meta-analysis found that higher intake was associated with lower fracture risk. Because most dietary vitamin K is K1 from leafy greens, it speaks more directly to phylloquinone than the supplement trials do. * [Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/32977548/) - Vlasschaert et al., 2020 A deliberately skeptical review of controlled trials that concludes vitamin K supplementation reliably improves calcification biomarkers but has not yet been shown to reduce hard cardiovascular events. It is an important counterweight to the optimistic observational literature. ## Mechanism of Action Vitamin K1 is a fat-soluble vitamin whose single essential job is to act as a cofactor for one enzyme: gamma-glutamyl carboxylase (GGCX — the enzyme that switches on vitamin K–dependent proteins). This enzyme adds a chemical group to specific building blocks in a small set of proteins, converting them into gamma-carboxyglutamate (Gla) residues. Only after this activation can these proteins grip calcium and do their jobs. The vitamin K–dependent proteins fall into two groups: * **Clotting proteins made in the liver:** factors II (prothrombin), VII, IX, and X, plus the anticoagulant proteins C, S, and Z. This is the coagulation function. * **Proteins acting outside the liver:** osteocalcin (helps bind calcium into bone) and matrix Gla protein (MGP — inhibits calcium deposits in arteries and soft tissue), among others. During each activation, vitamin K is used up and converted to an inactive "epoxide" form. It is then regenerated by the enzyme vitamin K epoxide reductase (VKORC1 — the recycler that lets a small amount of vitamin K be reused many times). This recycling loop, the vitamin K cycle, is exactly what warfarin-type blood thinners block, which is why they deplete active vitamin K. There is competing nuance about where K1 acts. Because phylloquinone is cleared quickly and taken up preferentially by the liver, some researchers argue it mainly supports clotting and contributes little to bone and artery proteins compared with the longer-lasting K2 (menaquinone) forms. Others point out that the body can convert some K1 into the tissue form MK-4 (via the enzyme UBIAD1), and that dietary K1 — the dominant source of vitamin K for most people — is associated with the same extra-hepatic benefits. Both views are actively debated. As a compound, phylloquinone has a short circulating half-life (on the order of one to a few hours), is absorbed in the small intestine only in the presence of dietary fat and bile, and travels in triglyceride-rich lipoprotein particles. It is not a strong substrate for the classic drug-metabolizing enzymes; instead it is broken down mainly by side-chain shortening (involving the liver enzyme CYP4F2 — which helps clear vitamin K) followed by glucuronidation and excretion in bile and urine. The body stores relatively little vitamin K, so status depends heavily on recent intake. ## Historical Context & Evolution Vitamin K was discovered in 1929 by the Danish scientist Henrik Dam, who observed that chicks fed a fat-free diet developed bleeding. He named the missing factor the "Koagulationsvitamin" — hence the letter K. The plant form isolated from alfalfa was named phylloquinone (vitamin K1), and Edward Doisy later determined its chemical structure; Dam and Doisy shared the 1943 Nobel Prize in Physiology or Medicine for this work. For its first several decades, vitamin K1's role was understood almost entirely in terms of blood clotting. Its original and still-approved medical uses reflect this: preventing vitamin K deficiency bleeding in newborns, and reversing the effect of warfarin-type blood thinners when clotting is dangerously low. The synthetic drug form used clinically is called phytonadione. The shift toward health optimization began in the 1970s and 1980s, when the same vitamin K–dependent activation was discovered in proteins outside the liver — notably osteocalcin in bone and matrix Gla protein (MGP) in the artery wall. This reframed vitamin K as a nutrient for bone and vascular health, not just clotting. When describing this evolution, it is important to note that opinion has not simply "settled." Early observational findings that higher vitamin K intake tracks with fewer fractures and less artery calcification prompted excitement, but several later randomized trials of K1 failed to confirm benefits on hard endpoints such as bone density. New evidence has continued to arrive on both sides: participant-level cohort analyses have strengthened the mortality association, while controlled trials have repeatedly shown that improving calcification biomarkers does not automatically translate into fewer heart attacks or fractures. The current standing is genuinely open rather than resolved. ## Expected Benefits Benefits below are framed for health- and longevity-oriented adults who are already generally well-nourished, and are grouped by the strength of the underlying evidence. A dedicated search of clinical trials, cohort studies, and expert sources was performed to ensure the profile is complete. ### High 🟩 🟩 🟩 #### Normal Blood Clotting and Prevention of Deficiency Bleeding Vitamin K1's role in activating the liver's clotting proteins is the most firmly established benefit in all of nutrition science. Adequate intake keeps prothrombin time (the standard clotting test) normal and prevents the bleeding seen in frank deficiency; supplemental or injectable K1 reliably reverses over-thinned blood. For the target audience this benefit is mostly about not being deficient rather than about "boosting" clotting above normal, since the system is self-limiting once proteins are fully activated. **Magnitude:** Restores clotting proteins to full activity within hours to days; correcting deficiency normalizes an elevated international normalized ratio (INR — a standardized clotting measure) and stops abnormal bleeding. ### Medium 🟩 🟩 #### Improved Activation of Bone and Vascular Proteins (Carboxylation Status) Beyond clotting, K1 supplementation consistently and dose-dependently increases the activated (carboxylated) fraction of osteocalcin and matrix Gla protein, reducing the circulating "undercarboxylated" forms that signal insufficient vitamin K. This is a biomarker benefit — it shows the vitamin is reaching and activating tissue proteins — and it is one of the most reproducible findings across randomized trials of phylloquinone. Whether this reliably translates into fewer fractures or heart attacks is where the evidence weakens, but the underlying biological effect itself is well demonstrated. **Magnitude:** Doses of roughly 500 µg–1 mg/day typically lower undercarboxylated osteocalcin by about 20–60% within several weeks. ### Low 🟩 #### Lower Risk of Death From Any Cause (Association) Pooled participant-level cohort data show that adults with the lowest circulating phylloquinone have a modestly higher risk of death over follow-up compared with those who are replete. The proposed explanation ranges from direct effects on vascular calcification to phylloquinone simply marking an overall healthy, vegetable-rich diet. The evidence is graded low because it is entirely observational: no randomized trial has tested whether raising K1 lowers mortality, and reverse causation and diet confounding are difficult to exclude. **Magnitude:** About 19% higher risk of death from any cause in those with the lowest circulating vitamin K1 (below ~0.5 nmol/L) versus higher levels (above ~1.0 nmol/L). #### Reduced Fracture Risk ⚠️ Conflicted Higher dietary vitamin K1 intake is associated with fewer hip and total fractures in observational studies, and pooled RCT data once suggested a protective effect. However, that pooled effect was driven mainly by high-dose K2 trials, and the largest dedicated K1 trial (5 mg/day for 2–4 years in postmenopausal women) found no improvement in bone mineral density. The picture is therefore genuinely mixed for phylloquinone specifically. **Magnitude:** Observational studies report roughly 20–50% lower fracture-related risk at the highest versus lowest intakes; dedicated K1 supplement trials show no measurable bone-density benefit. #### Slowed Arterial and Coronary Calcification ⚠️ Conflicted Because activated matrix Gla protein suppresses calcium deposition in artery walls, vitamin K has a plausible mechanism to slow the artery hardening that accompanies aging. A three-year trial of 500 µg/day K1 slowed coronary calcium progression, but only in the subgroup that took the supplement consistently, with no effect in the overall analysis. The strongest calcification evidence involves K2 (MK-7) rather than K1, keeping this benefit uncertain for phylloquinone. **Magnitude:** In adherent participants, roughly a 6% relative slowing of coronary calcium score progression over three years; null in intention-to-treat analysis. #### Lower Atherosclerotic Cardiovascular Disease Risk (Association) Large diet-and-health cohorts report that people with the highest vitamin K1 intake are less likely to be hospitalized for atherosclerotic cardiovascular disease (ASCVD — narrowing and hardening of the arteries). The signal is consistent in direction across populations but modest in size and, again, observational rather than causal. It aligns with the calcification mechanism but cannot confirm it. **Magnitude:** Approximately 20% lower risk of ASCVD-related hospitalization at the highest versus lowest K1 intake in a large Danish cohort. ### Speculative 🟨 #### Improved Insulin Sensitivity and Glucose Handling A small controlled study found that 500 µg/day of K1 for three years improved insulin sensitivity in older men, with no effect in women, and osteocalcin is mechanistically linked to glucose regulation. Because this rests on one modest, sex-limited trial plus supportive mechanism, it is treated as speculative and specific to certain subgroups only. #### Support of Cognitive Function in Aging Vitamin K is present in brain tissue and participates in the metabolism of certain fats (sphingolipids) that matter for nerve cells, and some observational work links higher status to better cognitive scores in older adults. No completed randomized trial confirms a cognitive benefit of K1, so this remains mechanistic and anecdotal, with a dedicated trial only now underway. ## Benefit-Modifying Factors The degree to which vitamin K1 helps a given person depends on several factors: * **Baseline vitamin K status:** Those who are already replete (a diet rich in leafy greens, low undercarboxylated osteocalcin) have little room to benefit, while people with poor status stand to gain the most from additional intake. * **Genetic variation:** Variants in APOE (a gene affecting fat and vitamin transport — the APOE4 form is linked to lower circulating vitamin K), and in CYP4F2 and VKORC1 (which govern vitamin K breakdown and recycling), can shift how much phylloquinone reaches tissues and how efficiently it is used. * **Baseline biomarker levels:** Elevated dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP — a marker of poor vitamin K status) or high undercarboxylated osteocalcin identifies people whose vascular and bone proteins are under-activated and who are therefore more likely to respond. * **Pre-existing health conditions:** Fat-malabsorption conditions (cholestatic liver disease, cystic fibrosis, prior bariatric surgery, chronic pancreatitis) reduce absorption; people with chronic kidney disease (CKD) tend to have markedly poor vitamin K status and higher calcification burden, potentially increasing the room for benefit. * **Sex-based differences:** Some effects appear sex-specific — for example, the insulin-sensitivity signal was seen in men but not women — and calcification and bone responses may differ between sexes, though data are limited. * **Age-related considerations:** Older adults, including those at the upper end of the target range, more often show subclinical undercarboxylation and greater existing artery calcification, so they may have more to gain than younger, replete adults. ## Potential Risks & Side Effects Vitamin K1 is one of the safest vitamins: oral phylloquinone has no established toxic dose, and no tolerable upper intake level (UL) has been set because harmful effects are essentially absent even at high oral intakes. A dedicated search of drug-reference and clinical sources was performed to ensure the risk profile is complete. The meaningful risks below relate chiefly to drug interactions and to the injectable clinical form, not to ordinary oral use. ### High 🟥 🟥 🟥 #### Antagonism of Warfarin and Other Vitamin K Antagonists For anyone taking warfarin-type blood thinners (vitamin K antagonists, or VKAs — drugs that work by blocking vitamin K recycling), added or fluctuating K1 directly opposes the medication, lowering the INR and raising the risk of dangerous clots. Even day-to-day swings in dietary or supplemental K1 can destabilize control. This is a genuine, well-documented, clinically important effect — not the vitamin being toxic, but the vitamin countering a drug. Notably, the newer direct oral anticoagulants (DOACs — such as apixaban and rivaroxaban) are not affected by vitamin K. **Magnitude:** Changes of even a few hundred micrograms per day in K1 intake can measurably shift INR and warfarin dose requirements; large supplemental doses can cause temporary warfarin resistance. ### Medium 🟥 🟥 #### Severe Reactions to Intravenous Phytonadione The injectable clinical form of K1 carries a well-recognized risk of severe allergic-type (anaphylactoid) reactions, including a small number of fatal cases, particularly when given rapidly into a vein. This is why hospitals prefer oral or slow, diluted administration. The risk is essentially confined to the parenteral drug form used in medical settings and does not apply to oral dietary supplements or food. **Magnitude:** Rare (well under 1% of intravenous doses) but potentially life-threatening; risk rises with rapid intravenous injection and is minimized by oral or slow diluted dosing. ### Low 🟥 #### Gastrointestinal Discomfort Oral vitamin K supplements are occasionally associated with mild gastrointestinal (GI — digestive tract) complaints such as nausea, stomach upset, or loose stools, usually at higher doses. These effects are minor, self-limiting, and often reduced by taking the supplement with food. They are the most common real-world complaint from otherwise healthy users. **Magnitude:** Not quantified in available studies. #### Injection-Site and Delayed Skin Reactions Intramuscular or subcutaneous K1 injection can cause local reactions, including uncommon delayed, itchy, eczema-like skin patches at the injection site (historically described as "Texier's disease"). Like the anaphylactoid risk, this is specific to the injected drug form rather than oral use. It is generally self-resolving but can persist for weeks. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Theoretical Excess-Clotting Risk in People Not on Blood Thinners It is sometimes assumed that extra vitamin K1 might "thicken" the blood or promote clots in healthy people. In practice, once clotting proteins are fully activated the effect plateaus, and no controlled or observational evidence shows that supplemental K1 raises clot risk in individuals who are not taking vitamin K antagonists. This concern is therefore speculative and, on current evidence, unsupported; it is included to address a common misconception rather than a demonstrated harm. ## Risk-Modifying Factors Several factors change who is most likely to encounter a problem with vitamin K1: * **Concurrent anticoagulant therapy:** Being on warfarin or another vitamin K antagonist is by far the dominant risk modifier; for these individuals, consistency of intake matters more than the absolute amount. * **Genetic variation:** VKORC1 and CYP4F2 variants influence how sensitive a person is to the vitamin K–versus–warfarin balance and are already used to guide warfarin dosing; GGCX variants can alter protein activation. G6PD (an enzyme whose deficiency can trigger red-blood-cell breakdown) is relevant only to the synthetic K3 form (menadione), not to K1. * **Baseline biomarker levels:** A person's INR and vitamin K status at baseline determine how much a given intake will move the needle; those tightly controlled on warfarin are most vulnerable to destabilization. * **Pre-existing health conditions:** Liver disease, fat-malabsorption states, and mechanical heart-valve or clotting disorders that mandate anticoagulation all raise the stakes of changing K1 intake. Kidney disease patients often take vitamin K deliberately but require coordination if also anticoagulated. * **Sex-based differences:** No consistent sex difference in vitamin K1 risk has been established; the safety profile appears similar in men and women. * **Age-related considerations:** Older adults are more likely to be on anticoagulants and multiple medications, so the interaction risk — rather than any direct toxicity — rises with age and polypharmacy. ## Key Interactions & Contraindications * **Warfarin and other vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon):** Direct antagonism. **Severity:** major/caution. **Consequence:** reduced anticoagulation and higher clot risk, or unstable INR. **Mitigation:** keep vitamin K intake consistent and coordinate any change with the anticoagulation clinic; do not start or stop supplements abruptly. * **Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran):** No meaningful interaction — these do not work through vitamin K. **Severity:** none. This is a useful distinction for people who assume all blood thinners interact. * **Fat-absorption–blocking drugs (orlistat — prescription and over-the-counter; bile-acid sequestrants such as cholestyramine and colesevelam; mineral oil):** Reduce absorption of fat-soluble vitamins including K1. **Severity:** caution. **Consequence:** lower vitamin K status over time. **Mitigation:** separate dosing by several hours and monitor status with prolonged use. * **Broad-spectrum antibiotics (cephalosporins, fluoroquinolones, metronidazole):** Can lower gut bacterial vitamin K2 production and, in people on warfarin, potentiate anticoagulation. **Severity:** caution. **Mitigation:** monitor INR during and after prolonged courses. * **High-dose vitamin E (over-the-counter supplement, typically >800 IU/day):** Can antagonize vitamin K and, at high doses, increase bleeding tendency. **Severity:** caution (additive with anticoagulants). **Mitigation:** avoid combining megadose vitamin E with anticoagulants. * **Supplements with additive or synergistic effects:** Vitamin D3, vitamin K2 (MK-4 and MK-7 — the animal and fermented forms), calcium, and magnesium act along the same bone-and-calcium pathway; combining them is generally complementary rather than harmful, but stacking multiple vitamin K forms should be counted toward total intake if anticoagulated. * **Populations who should exercise particular caution:** People taking vitamin K antagonists (must maintain stable intake rather than avoid entirely), those with a known hypersensitivity to injectable phytonadione (relevant to the drug form), and individuals with significant fat malabsorption who may need monitored dosing. ## Risk Mitigation Strategies * **Keep intake consistent if on warfarin:** The goal for anticoagulated users is stability, not avoidance — a steady daily amount of dietary and supplemental K1 prevents the INR swings that cause both clotting and bleeding. This directly mitigates the dominant warfarin-antagonism risk. * **Coordinate changes with anticoagulation monitoring:** Any planned start, stop, or dose change of a K1 supplement while on a vitamin K antagonist should be paired with more frequent INR checks (for example, weekly until stable) to catch destabilization early. This prevents under- or over-anticoagulation. * **Prefer oral over injectable forms outside clinical settings:** Because the serious anaphylactoid and injection-site reactions are tied to the parenteral form, using oral K1 for everyday supplementation avoids those specific risks entirely. * **Take with a fat-containing meal:** Dosing K1 alongside dietary fat improves absorption and reduces the occasional gastrointestinal upset, addressing both the minor GI side effect and the risk of underdosing from poor absorption. * **Avoid megadose vitamin E co-supplementation:** Keeping supplemental vitamin E below roughly 400 IU/day when using vitamin K (and especially when on any blood thinner) avoids the additive bleeding tendency that high-dose vitamin E can create. * **Screen for malabsorption when relevant:** For people with cholestatic liver disease, cystic fibrosis, or post-bariatric anatomy, periodically checking vitamin K status (see the monitoring section) prevents silent deficiency despite adequate intake. ## Therapeutic Protocol There is no single validated "longevity dose" of vitamin K1; protocols range from meeting basic adequacy to the higher doses used in research, and leading practitioners typically fold K1 into a broader bone-and-vascular stack. * **Baseline adequacy target:** The US Adequate Intake (AI — the intake assumed sufficient for most people) is about 120 µg/day for men and 90 µg/day for women, readily met by a serving or two of leafy greens. This is the floor most integrative clinicians start from. * **Research-range supplementation:** Trials targeting bone markers, calcification, or insulin sensitivity have used roughly 500 µg/day up to 5 mg/day of phylloquinone. Lower end (500 µg–1 mg/day) is the more common "optimization" range; the 5 mg/day dose comes from bone trials. * **Conventional versus integrative framing:** The conventional approach treats K1 mainly as a dietary adequacy and clotting nutrient and questions supplementation in replete adults; the integrative approach (popularized in part through functional-medicine writers such as Chris Kresser and by vitamin K researchers) pairs K1 or K2 with vitamin D3 and calcium to direct calcium toward bone and away from arteries. Neither is presented here as the default. * **Best time of day and with food:** Because K1 is fat-soluble, taking it with the largest fat-containing meal of the day maximizes absorption; specific clock time appears unimportant. * **Half-life and dosing frequency:** Phylloquinone's short circulating half-life (hours) means once-daily dosing is standard and sufficient for maintaining tissue protein activation; there is no established advantage to splitting doses for K1 specifically, though some protocols split combined K1/K2/D formulas simply for tolerability. * **Genetic considerations:** Carriers of CYP4F2 or VKORC1 variants (which alter vitamin K turnover) and APOE4 carriers (lower circulating vitamin K) may reach different tissue levels at the same dose, a factor more established for warfarin dosing than for supplementation targets. * **Sex and age considerations:** Older adults and those with poor baseline status are the most plausible responders; the limited sex-specific data (for example, insulin effects seen in men) suggest responses are not uniform. * **Baseline biomarkers and conditions:** Practitioners who measure dp-ucMGP or undercarboxylated osteocalcin use elevated values to justify higher-end dosing, and adjust upward in malabsorption or chronic kidney disease where status is typically poor. ## Discontinuation & Cycling * **Lifelong versus short-term:** Vitamin K1 is best viewed as an ongoing dietary nutrient rather than a course of treatment; because the body stores little and turnover is rapid, any tissue benefit depends on continued adequate intake. * **Withdrawal effects:** There are no withdrawal or rebound effects from stopping K1. Status simply returns to whatever the diet supplies, generally within days, and clotting remains normal as long as diet is adequate. * **Tapering:** No taper is needed for K1 itself. The one exception is people on warfarin, for whom any change in K1 intake should be gradual and monitored to avoid destabilizing the INR — a coordination issue, not a true taper. * **Cycling:** Cycling is not recommended or necessary; there is no evidence of tolerance or diminishing effect that cycling would address, and steady intake is preferable for consistent protein activation. ## Sourcing and Quality * **Form and isomer:** Supplemental K1 should be trans-phylloquinone, the biologically active isomer; reputable products specify this, and oil-based softgels are generally better absorbed than dry tablets because K1 is fat-soluble. * **Third-party testing:** Independent verification (USP, NSF, or ConsumerLab) matters because vitamin K products have been found to contain less than labeled — ConsumerLab has reported a product with only about 81% of its stated vitamin K. Choosing tested products guards against underdosing and contamination. * **Combination products:** K1 is frequently sold alongside K2 (MK-7), vitamin D3, and minerals; buyers should read labels to know exactly how much phylloquinone they are getting and to avoid unintentionally high combined vitamin K intake if anticoagulated. * **Reputable brands and sources:** Established supplement makers with third-party testing (for example, Thorne, Life Extension, and Bluebonnet, which offers a stand-alone K1 product) are reasonable choices; whole-food leafy greens remain the most reliable and inexpensive source of K1. ## Practical Considerations * **Time to effect:** Biomarkers of vitamin K activation (carboxylated osteocalcin, dp-ucMGP) shift within days to a few weeks, but any effect on bone density, artery calcification, or clinical outcomes unfolds over months to years. * **Common pitfalls:** Taking K1 without dietary fat (reducing absorption), confusing K1 with K2 and assuming they are interchangeable, expecting megadoses to add benefit once proteins are saturated, and — most importantly — changing intake erratically while on warfarin. * **Regulatory status:** As a dietary supplement, vitamin K1 is regulated in the US as a food, not a drug; the injectable and tablet forms of phytonadione are separately FDA-approved medicines for deficiency and anticoagulant reversal. * **Cost and accessibility:** Vitamin K1 is inexpensive, widely available over the counter, and abundant in common vegetables, so neither cost nor access is a meaningful barrier. ## Interaction with Foundational Habits * **Sleep:** No direct interaction is established — vitamin K1 is not known to affect sleep onset, quality, or circadian timing, and there is no reason to time it around sleep. The relationship is best characterized as none. * **Nutrition:** The interaction here is direct and central. K1 requires dietary fat and bile for absorption, so it is best consumed with fat-containing meals; leafy greens are its main dietary source; and it works cooperatively with vitamin D3 and calcium in bone-and-vascular metabolism. Practically, pairing greens with olive oil or another fat improves uptake, while megadose vitamin E can blunt vitamin K's action. * **Exercise:** No direct effect on exercise performance or recovery is established (the interaction is essentially none/indirect). Its potential bone- and vascular-supporting roles are complementary to the well-proven skeletal and cardiovascular benefits of physical activity rather than additive to any workout response. * **Stress management:** No meaningful interaction with the stress-hormone (cortisol) system has been demonstrated; the direction is none. Vitamin K1 is not known to influence, or be influenced by, psychological stress or relaxation practices. ## Monitoring Protocol & Defining Success Baseline testing is worthwhile mainly for people who are anticoagulated, suspected of malabsorption, or specifically pursuing vascular and bone goals; for most replete adults, formal lab monitoring is optional. Before starting, a clotting test and, where available, a functional vitamin K marker establish the starting point. Ongoing monitoring depends on the reason for use: those on warfarin need INR checks tied to any intake change (for example, weekly until stable, then per their usual schedule), while those tracking vascular status might repeat a functional marker every 6–12 months. * Baseline labs and tests: prothrombin time/INR, and — if pursuing bone or vascular goals — a functional vitamin K marker such as dp-ucMGP or undercarboxylated osteocalcin. * Ongoing labs and tests: INR as above for anticoagulated users; functional markers (dp-ucMGP) every 6–12 months for those targeting calcification or bone. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Prothrombin time / INR | ~0.8–1.1 (not anticoagulated) | Confirms clotting is normal and detects deficiency or drug effect | Essential for anyone on a vitamin K antagonist; conventional labs report it routinely; not a sensitive marker of mild deficiency | | Dephospho-uncarboxylated matrix Gla protein (dp-ucMGP) | Lower is better; roughly <400–500 pmol/L reflects good vitamin K status | Functional marker of how well vitamin K is activating the artery-protective protein | High values indicate poor status and greater room to benefit; used mainly in research and functional-medicine settings; conventional reference ranges run higher than the functional target | | Undercarboxylated osteocalcin (%ucOC) | Lower is better | Reflects vitamin K availability for bone protein activation | Falls with adequate K1 intake; best paired with total osteocalcin; not a standard clinical test | | PIVKA-II | Undetectable / very low | Most sensitive marker of subclinical vitamin K deficiency | Protein induced by vitamin K absence; rises early when status is poor; useful in malabsorption; specialized assay | | Plasma phylloquinone | Above ~1.0 nmol/L (levels <0.5 nmol/L linked to higher mortality) | Directly reflects recent K1 intake and status | Fasting sample preferred; strongly influenced by the last meal, so interpret alongside diet; measured in research and specialty labs | Qualitative markers of success and of deficiency include: * Absence of easy bruising, bleeding gums, or frequent nosebleeds (classic signs of poor vitamin K status). * Stable, in-range clotting control for those on anticoagulants. * Over the long term, maintained bone density and stable vascular calcification scores, recognizing these are influenced by many factors beyond vitamin K. ## Emerging Research Research on vitamin K1 is shifting from biomarkers toward whether the plant form changes real outcomes such as cognition, bone, and hard cardiovascular events. Findings are framed here for proactive, health-oriented adults rather than the general population. * **Vitamin K and cognition in coronary heart disease (NutriCog):** A placebo-controlled trial testing whether vitamin K supplementation improves general cognition, processing speed, executive function, and memory in people with coronary heart disease. [NCT06855953](https://clinicaltrials.gov/study/NCT06855953) — approximately 40 participants; primary endpoint is change in overall cognitive functioning. * **Bioavailability of vitamin K vitamers:** A study using carbon-labelled (13C) vitamin K to directly compare how the different forms — including K1 (phylloquinone) — are absorbed and distributed, which could clarify the long-standing K1-versus-K2 debate. [NCT07041645](https://clinicaltrials.gov/study/NCT07041645) — about 20 participants; measures labelled vitamers in blood, urine, and stool. * **Vitamin K in bone homeostasis:** A trial adding vitamin K (with other nutrients) to calcium and vitamin D to test effects on bone-related outcomes, relevant to the still-unsettled fracture question. [NCT07256769](https://clinicaltrials.gov/study/NCT07256769) — about 134 participants at elevated bone risk. * **The central open question — hard outcomes versus biomarkers:** The most important future work concerns whether raising vitamin K1 actually reduces deaths, fractures, or heart attacks, given that supplementation reliably improves calcification and carboxylation markers but has not yet moved hard endpoints. This gap is laid out directly by [Vlasschaert et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32977548/), while the mortality association motivating such trials comes from [Shea et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32359159/). Both strengthening evidence (consistent cohort signals) and weakening evidence (null trials on bone density and events) continue to accumulate. * **Personalized dosing by genotype:** Future studies may tailor vitamin K targets to CYP4F2, VKORC1, and APOE genotype, which affect turnover and circulating levels; this could explain why uniform doses produce uneven results across individuals. ## Conclusion Vitamin K1 is the plant form of vitamin K, obtained mainly from leafy greens, and its one essential job is switching on a small set of proteins that control clotting and guide calcium into bone and away from arteries. On that core clotting role the evidence is as solid as nutrition science gets, and preventing shortfall clearly matters. The longevity story is more tentative. People with higher intake or higher blood levels tend to live longer and have fewer fractures and less artery hardening, and supplements dependably improve the laboratory signs of vitamin K activity. Yet the studies that assign the vitamin and follow people forward have generally not shown fewer heart attacks, stronger bones, or longer life, so the appealing population patterns may partly reflect a healthy, vegetable-rich diet rather than the vitamin itself. A recurring theme is that better test numbers have not reliably become better outcomes. For a health-focused adult, the practical takeaway is that vitamin K1 is inexpensive, remarkably safe by mouth, and easy to get from food, while its extra benefits beyond clotting remain promising but unproven. The one situation demanding real care is the use of warfarin-type blood thinners, where steady, coordinated intake is what counts. The evidence base is active, honest about its gaps, and still unfolding. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**